Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...

In a recent publication in Nature Communications, researchers from the Tumor Profiler consortium combined single-cell multi-omics and functional profiling for 21 AML patients to reveal resistance ...

As word of his diagnosis spread, friends, neighbors, and even strangers wanted to help. A small committee of friends and ...

Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences is advancing the development of its promising drug tuspetinib as part ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

Q3 2024 Earnings Call Transcript November 5, 2024 Operator: Good morning, everyone, and welcome to the Cellectis Third ...

Teachers and staff at McCourt Middle School, as well as the community at-large, took solidarity to a new level last Thursday, Oct. 31, during their Golden Glow Day ...